{"address1": "777 Old Saw Mill River Road", "city": "Tarrytown", "state": "NY", "zip": "10591-6707", "country": "United States", "phone": "914 847 7000", "website": "https://www.regeneron.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.", "fullTimeEmployees": 15158, "companyOfficers": [{"maxAge": 1, "name": "Dr. Leonard S. Schleifer M.D., Ph.D.", "age": 71, "title": "Co-Founder, President, CEO & Co-Chairman", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 6823034, "exercisedValue": 117275128, "unexercisedValue": 192379808}, {"maxAge": 1, "name": "Dr. George D. Yancopoulos M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, Chief Scientific Officer & Co-Chairman", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 6796783, "exercisedValue": 95717904, "unexercisedValue": 188321072}, {"maxAge": 1, "name": "Mr. Christopher R. Fenimore CPA", "age": 53, "title": "Executive VP of Finance & CFO", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1269250, "exercisedValue": 9054700, "unexercisedValue": 16618295}, {"maxAge": 1, "name": "Dr. Andrew J. Murphy Ph.D.", "age": 65, "title": "Executive Vice President of Research", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1613560, "exercisedValue": 26279800, "unexercisedValue": 56244512}, {"maxAge": 1, "name": "Mr. Daniel P. Van Plew", "age": 51, "title": "Executive VP and GM of Industrial Operations & Product Supply", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 1905481, "exercisedValue": 20283170, "unexercisedValue": 9502018}, {"maxAge": 1, "name": "Ms. Patrice  Gilooly", "title": "Senior Vice President of Quality Assurance & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  McCowan", "title": "Senior VP of IT & Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Crowe", "title": "Senior Vice President of Investor Relations & Strategic Analysis", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph J. LaRosa J.D.", "age": 65, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1748110, "exercisedValue": 23227300, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Lozner", "title": "Senior VP & Chief Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://newsroom.regeneron.com/", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 614.79, "open": 613.055, "dayLow": 597.9192, "dayHigh": 616.5899, "regularMarketPreviousClose": 614.79, "regularMarketOpen": 613.055, "regularMarketDayLow": 597.9192, "regularMarketDayHigh": 616.5899, "dividendRate": 3.52, "dividendYield": 0.57, "exDividendDate": 1747699200, "payoutRatio": 0.0224, "beta": 0.426, "trailingPE": 15.348159, "forwardPE": 13.329287, "volume": 734733, "regularMarketVolume": 735063, "averageVolume": 1153000, "averageVolume10days": 1406850, "averageDailyVolume10Day": 1406850, "bid": 603.21, "ask": 650.03, "bidSize": 1, "askSize": 2, "marketCap": 65205465088, "fiftyTwoWeekLow": 520.5, "fiftyTwoWeekHigh": 1211.2, "priceToSalesTrailing12Months": 4.629196, "fiftyDayAverage": 604.626, "twoHundredDayAverage": 809.66064, "trailingAnnualDividendRate": 0.88, "trailingAnnualDividendYield": 0.0014313831, "currency": "USD", "tradeable": false, "enterpriseValue": 59317489664, "profitMargins": 0.31941998, "floatShares": 101658661, "sharesOutstanding": 106148000, "sharesShort": 2887463, "sharesShortPriorMonth": 2790935, "sharesShortPreviousMonthDate": 1743379200, "dateShortInterest": 1745971200, "sharesPercentSharesOut": 0.026700001, "heldPercentInsiders": 0.019019999, "heldPercentInstitutions": 0.92073, "shortRatio": 2.38, "shortPercentOfFloat": 0.028199999, "impliedSharesOutstanding": 107965000, "bookValue": 277.503, "priceToBook": 2.176373, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "earningsQuarterlyGrowth": 0.12, "netIncomeToCommon": 4499299840, "trailingEps": 39.35, "forwardEps": 45.31, "enterpriseToRevenue": 4.211, "enterpriseToEbitda": 13.267, "52WeekChange": -0.37508643, "SandP52WeekChange": 0.11936104, "lastDividendValue": 0.88, "lastDividendDate": 1747699200, "quoteType": "EQUITY", "currentPrice": 603.95, "targetHighPrice": 958.0, "targetLowPrice": 535.0, "targetMeanPrice": 797.21375, "targetMedianPrice": 802.0, "recommendationMean": 1.69231, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 8349400064, "totalCashPerShare": 79.017, "ebitda": 4471000064, "totalDebt": 2704800000, "quickRatio": 3.9, "currentRatio": 4.927, "totalRevenue": 14085699584, "debtToEquity": 9.204, "revenuePerShare": 130.878, "returnOnAssets": 0.0691, "returnOnEquity": 0.15961, "grossProfits": 6873699840, "freeCashflow": 2082887552, "operatingCashflow": 3953100032, "earningsGrowth": 0.159, "revenueGrowth": -0.037, "grossMargins": 0.48799, "ebitdaMargins": 0.31741, "operatingMargins": 0.19943, "financialCurrency": "USD", "symbol": "REGN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "fiftyTwoWeekChangePercent": -37.508644, "dividendDate": 1749168000, "earningsTimestamp": 1745922600, "earningsTimestampStart": 1753878600, "earningsTimestampEnd": 1754310600, "earningsCallTimestampStart": 1745929800, "earningsCallTimestampEnd": 1745929800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 39.35, "epsForward": 45.31, "epsCurrentYear": 35.50205, "priceEpsCurrentYear": 17.011694, "fiftyDayAverageChange": -0.67596436, "fiftyDayAverageChangePercent": -0.0011179877, "twoHundredDayAverageChange": -205.71063, "twoHundredDayAverageChangePercent": -0.2540702, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 670602600000, "regularMarketChange": -10.839966, "regularMarketDayRange": "597.9192 - 616.5899", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1153000, "fiftyTwoWeekLowChange": 83.45001, "fiftyTwoWeekLowChangePercent": 0.16032663, "fiftyTwoWeekRange": "520.5 - 1211.2", "fiftyTwoWeekHighChange": -607.24994, "fiftyTwoWeekHighChangePercent": -0.50136226, "corporateActions": [{"header": "Dividend", "message": "REGN announced a cash dividend of 0.88 with an ex-date of May. 20, 2025", "meta": {"eventType": "DIVIDEND", "dateEpochMs": 1747713600000, "amount": "0.88"}}], "regularMarketTime": 1747856908, "shortName": "Regeneron Pharmaceuticals, Inc.", "longName": "Regeneron Pharmaceuticals, Inc.", "regularMarketChangePercent": -1.7631983, "regularMarketPrice": 603.95, "exchange": "NMS", "messageBoardId": "finmb_33715", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "REGULAR", "displayName": "Regeneron Pharmaceuticals", "trailingPegRatio": 1.3226}